Quality by Design (QbD)

Quality by Design (QbD) constitutes a systematic, science-based approach to pharmaceutical development emphasising understanding product and process characteristics, identifying sources of variability, and implementing control strategies ensuring consistent quality rather than relying primarily on testing finished products. This paradigm shift from empirical development to knowledge-driven approaches employs risk assessment, design of experiments, and process analytical technology establishing design spaces within which process variations are understood and controlled. QbD principles, outlined in ICH Q8-Q11 guidelines, aim to build quality into products and processes from inception.

The biopharmaceutical industry has increasingly adopted QbD methodologies throughout development improving process understanding, robustness, and regulatory efficiency. Quality target product profile defines desired product characteristics ensuring patient needs guide development. Critical quality attributes represent product features ensuring efficacy and safety, identified through risk assessment. Process characterisation employs design of experiments systematically evaluating input variables and their interactions. Design space represents the multidimensional combination of variables demonstrated to provide quality assurance. Control strategy encompasses controls derived from process understanding ensuring consistent product quality. Regulatory benefits include enhanced flexibility for post-approval changes within design space and potentially fewer regulatory submissions. As manufacturing evolves through continuous processing and advanced analytics enable real-time monitoring, QbD continues transforming pharmaceutical development through science-based understanding.